Abstract
Endostatin, the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. At present, there are a large number of research papers on endostatin. However, the action mechanism of endostatin is still a matter of ongoing discussion. The objective of this review is to elucidate its origin and elementary structure, and to discuss its structure basis of activity and action mechanisms based on the latest research. Furthermore, some published studies reporting the antiangiogenic effects of endostatin-derived peptides were also reviewed. It is proposed that the amino acid sequence of endostatin contains both angiosuppressive and angiostimulatory domains. Short endostatin fragments may be exploited as a new angiogenesis inhibitor for therapeutic applications, in substitution of the full length endostatin. These studies on endostatin fragments also shed light on our understanding of the molecular action mechanisms of endostatin.
Keywords: Endostatin, angiogenesis, inhibit, structure, fragments, action mechanisms, amino acid residues, endothelial cells
Current Protein & Peptide Science
Title: Research Advances of Endostatin and its Short Internal Fragments
Volume: 9 Issue: 3
Author(s): Huan-Li Xu, Hai-Ning Tan, Feng-Shan Wang and Wei Tang
Affiliation:
Keywords: Endostatin, angiogenesis, inhibit, structure, fragments, action mechanisms, amino acid residues, endothelial cells
Abstract: Endostatin, the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. At present, there are a large number of research papers on endostatin. However, the action mechanism of endostatin is still a matter of ongoing discussion. The objective of this review is to elucidate its origin and elementary structure, and to discuss its structure basis of activity and action mechanisms based on the latest research. Furthermore, some published studies reporting the antiangiogenic effects of endostatin-derived peptides were also reviewed. It is proposed that the amino acid sequence of endostatin contains both angiosuppressive and angiostimulatory domains. Short endostatin fragments may be exploited as a new angiogenesis inhibitor for therapeutic applications, in substitution of the full length endostatin. These studies on endostatin fragments also shed light on our understanding of the molecular action mechanisms of endostatin.
Export Options
About this article
Cite this article as:
Xu Huan-Li, Tan Hai-Ning, Wang Feng-Shan and Tang Wei, Research Advances of Endostatin and its Short Internal Fragments, Current Protein & Peptide Science 2008; 9 (3) . https://dx.doi.org/10.2174/138920308784534050
DOI https://dx.doi.org/10.2174/138920308784534050 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Design of Curcumin loaded Cellulose Nanoparticles for Prostate Cancer
Current Drug Metabolism Nanoparticles for Gene Delivery: A Brief Patent Review
Recent Patents on Drug Delivery & Formulation The Cancer Preventive Effects of Edible Mushrooms
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Pharmaceutical Design RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Synthesis and Cytotoxic Activity of 4-Aryl-4H-chromeno[4,3-d] [1,2,3] selenadiazoles
Letters in Drug Design & Discovery Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Cancer Therapy Based on a Mechanism of Action for Controlling the Immune System and the Resulting Patent Portfolio
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Chitosan Nano-encapsulation Enhances Gedunin Cytotoxicity A gainst Human Non-small-cell Lung Cancer (NCI-H292) Cell Line
Drug Delivery Letters Synthesis and Evaluation of Cytotoxicity of Novel Coumarin Peptide Alcohol Derivatives
Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers The Immune System in Cancer Prevention, Development and Therapy
Anti-Cancer Agents in Medicinal Chemistry Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Current Pharmaceutical Design Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Importance of Kier-Hall Topological Indices in the QSAR of Anticancer Drug Design
Current Computer-Aided Drug Design Multi-target Drug Discovery via PTML Modeling: Applications to the Design of Virtual Dual Inhibitors of CDK4 and HER2
Current Topics in Medicinal Chemistry